FDA records linked by MedtechLedger identify Endoclot Plus Co., Ltd. as the applicant on a single 510(k) premarket notification in the retrieved collection: K260997, decided September 9, 2026. The filing covers SIS BLU (SISBLU-30-01) and SIS BLU (SISBLU-15-01), classified as a Submucosal Injection Agent in the Gastroenterology, Urology advisory committee area. The manufacturer’s own site describes EndoClot Plus Co., Ltd. as established in Suzhou Industrial Park, China in 2014 to manufacture EndoClot product lines. [1][3][4]
The K260997 filing and its scope
K260997 was received March 26, 2026 and decided September 9, 2026 with decision code SESE, described by FDA as Substantially Equivalent. The clearance type is Traditional, the third-party review flag is N, and the statement or summary field reads Summary. The device is listed under product code PLL, regulation number 876.1500, device class 2, with the advisory committee recorded as GU, Gastroenterology, Urology. [1][3]
The Innolitics record of the same filing lists the classification name as Submucosal Injection Agent and names two legally marketed predicate devices: ORISE Gel (K180068, product code PLL) and EndoClot (K191254, product code PLL). The device description in that record states SIS BLU is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers or other gastrointestinal mucosal lesions, prior to excision with a snare or other endoscopic device. [3]
Applicant identity and address of record
The FDA record gives the applicant as Endoclot Plus Co., Ltd., with a contact named Huihui Xie and an address at Unit 101, B8 Bldg., 218 Xinghu St., Suzhou Industrial Park, (Jiangsu) Pilot Free Trade Zone Suzhou Area, Suzhou, 215000, country code CN. That address is the filing address of record; it is not treated here as a verified corporate headquarters. [1][2]
The manufacturer’s published documentation describes EndoClot Plus, Inc. (EPI) as a privately held medical device company in Santa Clara, California, and states that EndoClot Plus Co., Ltd. was established in Suzhou Industrial Park, China in 2014 to manufacture the EndoClot product lines. The relationship between the two named entities is described only in that manufacturer text; no ownership structure is verified in the FDA records reviewed. [4]
Documented product lines
The manufacturer’s site lists products as EndoClot PHS, EndoClot Adhesive and EndoClot SIS, and describes EndoClot PHS as a polysaccharide hemostatic system that sprays a proprietary powder directly to the wound during endoscopy. The same text states the Suzhou entity was established to manufacture the EndoClot product lines including EndoClot PHS, EndoClot Adhesive and EndoClot Submucosal Injection System. [4]
Within the retrieved FDA collection, the only linked premarket record for this applicant is K260997 covering SIS BLU (SISBLU-30-01) and SIS BLU (SISBLU-15-01). The collection contains one linked record, one 510(k) pathway entry and one SESE decision; the record sample likewise holds one entry with one SESE decision. These counts describe the retrieved filings as of November 20, 2026 and are not a measure of total portfolio, sales or safety performance. [1][3]
Reading the record with care
The FDA notification pages for K260997 repeat the applicant name, the Suzhou Industrial Park address and the Gastroenterology specialty, and carry standard FDA contact information rather than product performance data. No clearance for EndoClot PHS, EndoClot Adhesive or the broader Submucosal Injection System appears among the numbered sources, so their regulatory status is unknown here. [2][5]
Claims about clinical performance, comparative benefit, commercial availability or customer adoption for SIS BLU are not supported by the records reviewed. The documented facts are the applicant identity, the two model designations, the PLL classification, the predicate listings and the manufacturer’s own product descriptions. [1][3][4]

